Tech Company Financing Transactions
Werewolf Therapeutics Funding Round
Longwood Fund, MPM Capital and Arkin Bio-Ventures participated in a $56 million Series A funding round for Werewolf Therapeutics. The round was recorded on 11/21/2019.
Transaction Overview
Company Name
Announced On
11/21/2019
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series A
Investors
Longwood Fund (Lead Investor)
MPM Capital (Lead Investor) (Luke Evnin)
Proceeds Purpose
The Series A financing will enable Werewolf to invest in research, talent acquisition and advancement of its platform and therapeutic programs to early clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1030 Massachusetts Ave. 210
Cambridge, MA 02138
USA
Cambridge, MA 02138
USA
Phone
Undisclosed
Website
Email Address
Overview
A werewolf is a creature that can shape-shift, changing from its unassuming human form into a dangerous predator under specific conditions. Werewolf Therapeutics is developing medicines designed to be delivered systemically, but remain inactive in the body until they reach the tumor microenvironment, where they stimulate a powerful immune response.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Daniel Hicklin
Chief Financial Officer
David Cordo
Chief Operating Officer
Reid Leonard
Chief Scientific Officer
Cynthia Seidel-Dugan
Vice President
Andres Salmeron
Vice President
Philipp Steiner
VP - R & D
William Winston
Browse more venture capital transactions:
Prev: 11/21/2019: Proletariat venture capital transaction
Next: 11/21/2019: Superpedestrian venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs